sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_3382> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_3382> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB08871> ;
    a rdf:Statement ;
    rdfs:label "halaven is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting 1 1 unresectable or metastatic liposarcoma who have received a prior anthracycline containing regimen 1 2 halaven is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting see clinical studies 14 1 halaven is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline containing regimen see clinical studies 14 2" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB08871> bl:category bl:Drug .
}